Liraglutide's Impact on Gut Microbiome Composition Explored in Obese and Overweight Subjects

Obesity and overweight conditions are major global health challenges, often associated with metabolic comorbidities like pre-diabetes. Current treatments, including GLP-1 receptor agonists like liraglutide, effectively promote weight loss and improve glycemic control. However, the full spectrum of mechanisms contributing to these benefits is still being elucidated. Emerging evidence suggests a significant role for the gut microbiome in regulating host metabolism, energy balance, and inflammation. Investigating how liraglutide modulates the gut microbiota could uncover novel pathways influencing its therapeutic effects and potentially identify new targets for enhancing treatment outcomes. This study aims to bridge that knowledge gap.

Researchers conducted a multicenter, randomized, double-blind, placebo-controlled trial over 28 weeks. A total of 300 non-diabetic obese subjects or overweight subjects with comorbidities were enrolled. Participants were randomized in a 2:1 ratio to receive once-daily subcutaneous injections of either liraglutide 3.0 mg or placebo. The primary objective was to investigate the composition of the gut microbiota, assessed from baseline to the end of treatment. While the abstract specifies the study design, it does not detail the specific sequencing or bioinformatics methods used for microbiota analysis.

The abstract for this study explicitly states its primary outcome was "to investigate the composition of the gut microbiota from baseline to end of treatment." However, the abstract does not present any specific findings, data, statistical results, or conclusions regarding the observed changes (or lack thereof) in gut microbiota composition following liraglutide treatment. Therefore, no quantitative or qualitative results can be reported from the provided information.